We are talking about the drugs “Baricitinib” and “Sotrovimab”.
The World Health Organization on Friday, January 14, approved two new drugs for the treatment of COVID-19.
This is reported by The Guradian with reference to AFP.
It is noted that the arthritis drug baricitinib, which was used along with corticosteroids to treat severe or critical patients with coronavirus, led to improved survival rates and a decrease in the need for mechanical ventilation (ventilators).
WHO indicated the relevant information in its recommendations published in the British medical journal BMJ.
The experts also approved treatment with Sotrovimab synthetic antibodies for patients at high risk of hospitalization who have a mild course of coronavirus infection.
This applies in particular to the elderly and those with immunodeficiency or chronic diseases such as diabetes.
At the same time, the benefit of “Sotrovimab” for people who do not have the risk of hospitalization was insignificant. The WHO also stressed that the effectiveness of the drug against new variants, in particular Omicron, “is still unclear.”
Previously, the European Medicines Agency (EMA) recommended marketing authorization for the drug Sotrovimab, indicating that it reduces the risk of hospitalization or death in adults by 79%.
